MMR may not be indicated in the CCL-deficient stifle stabilized by TPLO.

Compromised function of the meniscus by either MMR or MCH result in stress concentration which may predispose to osteoarthritis.

A spreadsheet-based model was developed to estimate the economic effect of varying reproductive performance in dairy herds. Scenarios were created to model an average cow with respect to production, herd lifetime, and reproductive events. Average milk yield per day of life as well as lifetime calf and replacement heifer production were examined. Additional inputs representing milk, feed, semen, calf, and salvage prices were used to calculate net cash flow for each day of herd life for the average cow in a scenario. Economic comparison of different scenarios was accomplished using an equivalent annual cash flow (annuity) methodology.Herd performance measures and prices representative of Ohio dairy herds were used to establish a baseline average cow that had a 160-d calving-to-conception interval [days open (DO)]. Alternative scenarios that differed from baseline in DO, annual culling rate, and feed and milk prices were created to characterize the effects of changes. Under scenario inputs representative of typical Ohio dairy herds, the model indicated that a lower annual culling rate (25%) was preferable to higher annual culling rates (34 or 45%). The model estimated maximum average milk yield per day of life to occur at 110 DO. At 34% annual culling rate, calves and replacement heifers produced per lifetime declined as DO increased; beyond 150 DO, the modeled cow produced less than 1 replacement heifer per lifetime. The model also estimated a loss of $1.37 per cow per year for a 1-d increase in DO beyond 160 d. At 20% higher feed and milk prices, the model estimated a loss of $1.52 per cow per year; at 20% lower feed and milk prices, the model estimated a loss of $1.23 per cow per year. Furthermore, the model suggested that the loss associated with a 1-d increase in DO changed as DO changed. Using baseline inputs, the model calculated losses for a 1-d increase of $0.44 per cow per year at 130 DO and $1.71 per cow per year at 190 DO. The nonuniform nature of the cost of additional DO is important to veterinarians and producers. The implication is that inefficient reproduction becomes marginally more costly to producers as performance declines and warrants increased attention. Conversely, marginal benefits of improved reproduction decrease as performance improves. Herds with strong reproductive performance have less opportunity to capture economic benefits of improvement.

A survey was conducted to collect information on nutrient management practices on dairy farms in south-central Pennsylvania. Of the 994 responding farms, the average farm consisted of 64 lactating cows, 10 dry cows, 41 heifers, and 17 calves with 69.7 ha of tillable land. Manure from lactating cows was mainly collected on a daily basis (84% of the farms) and stored as slurry or liquid (73%), while dry cow and heifer manure was collected weekly or less frequently (69 and 85% of the farms) and stored as solid stack or bedded pack (67 and 82%). Manure utilization featured consistent use of on-farm spreading, with limited incorporation, to corn or small grain fields before planting. Spreading on perennial forages or pasture was also common. Irrigation or injection of manure occurred on less than 5% of the farms. Only 20% of the farms reported manure nutrient testing, contrasting to over 90% for soil testing. Farm advisors and their services can be of vital importance in helping producers make conscientious management decisions for enhanced nutrient utilization. For example, ration balancing involved the services of feed and mineral sales representatives (85% of the farms), independent consultants (12%), and veterinarians (5%). Manure nutrient crediting to determine manure application rates was made by fertilizer dealers (40%), crop advisors and independent consultants (31%), and others. Nutrient management strategies and efforts must address the specific needs of farms with different animal densities and nutrient balances in order to be effective and applicable on the majority of farms.

BackgroundThe novel isoxazoline molecule fluralaner provides 12 weeks activity against fleas and 8 to 12 weeks against tick infestations according to label claims.MethodsThis blinded, multi-center study in client-owned dogs evaluated the flea control provided by a single oral fluralaner treatment (25–56 mg/kg; Bravecto™, Merck Animal Health) compared to a control group administered three oral spinosad (30 – 60 mg/kg; Comfortis®, Elanco) treatments at 4-week intervals together with an amitraz collar (9%, Preventic®, Virbac). Households were randomized (3:1 ratio) to either fluralaner (224 dogs, 118 households) or control (70 dogs, 39 households). Within households, one primary dog with at least 10 live fleas at enrollment was randomly selected for whole body flea counts every 4 weeks through Week 12; all dogs were followed for safety until Week 12. Fluralaner dogs received two additional doses at Weeks 12 and 24 for further safety and palatability observations through Week 26.ResultsGeometric mean flea count reductions from baseline for the fluralaner group at Weeks 4, 8, and 12 were 99.7%, 99.8%, and 99.8%, respectively; and 96.1%, 99.5%, and 99.6% for the spinosad controls. Percentages of flea-free primary dogs at Weeks 4, 8, and 12 were 91.1%, 95.4%, and 95.3% for the fluralaner group; and 44.7%, 88.2%, and 84.4% for the controls; the differences were significant at Weeks 4 (P < 0.0001) and 12 (P = 0.0370). Improvements in veterinarian assessed flea allergy dermatitis (FAD) were observed in both groups. Fluralaner tablets were accepted free choice in over 90% of doses. The most common adverse event was vomiting, occurring in 7.1% of the fluralaner group and 14.3% of the controls. No treatment related serious adverse events were reported.ConclusionsA single treatment of dogs with the palatable fluralaner flavored chewable tablet provides a safe and effective option for 12 weeks of flea control at least equivalent to that of 3 sequential treatments with spinosad tablets. Linked to the high level of flea control was a substantial alleviation of associated signs of FAD.